

POLYDEX PHARMACEUTICALS LIMITED

QUARTERLY DISCLOSURE REPORT

JULY 31, 2020

UNAUDITED

POLYDEX PHARMACEUTICALS LIMITED
QUARTERLY REPORT
JULY 31, 2020
UNAUDITED

INDEX

ITEM I	Name of Issuer	Page	3
ITEM II	Share Structure	Page	3
ITEM III	Consolidated Financial Statements		
	Interim Financial Statements	Page	4-9
	Notes to Interim Financial Statements	Page	10-17
ITEM IV	Management Discussion and Analysis	Page	18-26
ITEM V	Legal Proceedings	Page	27
ITEM VI	Defaults Upon Senior Securities	Page	27
ITEM VII	Other Information	Page	27
ITEM VIII	Exhibits	Page	27
ITEM IX	Certifications	Page	28-29

POLYDEX PHARMACEUTICALS LIMITED
QUARTERLY REPORT
JULY 31, 2020
UNAUDITED

ITEM I NAME OF ISSUER

Polydex Pharmaceuticals Limited
421 Comstock Road
Toronto, Ontario, Canada
M1L 2H5
Tel: (416) 755-2231
Fax: (416) 755-0334
Web: www.polydex.com

ITEM II SHARES OUTSTANDING

Preferred Stock – Class A

(i)	Period end date	July 31, 2020
(ii)	Authorized	100,000 shares at \$0.10 each
(iii)	Issued and outstanding	None
(iv)	Freely tradable shares (public float)	None
(v)	Number of shareholders of record	None

Preferred Stock – Class B

(i)	Period end date	July 31, 2020
(ii)	Authorized	899,400 shares at \$0.0167 each
(iii)	Issued and outstanding	899,400 shares
(iv)	Freely tradable shares (public float)	None
(v)	Number of shareholders of record	1

Common Stock

(i)	Period end date	July 31, 2020
(ii)	Authorized	10,000,000 shares
(iii)	Issued and outstanding	3,432,478 shares
(iv)	Freely tradable shares (public float)	2,561,166
(v)	Number of shareholders of record	220

POLYDEX PHARMACEUTICALS LIMITED
QUARTERLY REPORT
JULY 31, 2020
UNAUDITED

ITEM III INTERIM FINANCIAL STATEMENTS

CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)

TABLE OF CONTENTS

Consolidated Balance Sheets July 31, 2020 and January 31, 2020 (Unaudited)	5-6
Consolidated Statements of Operations and Comprehensive Income Three and six months ended July 31, 2020 and 2019 (Unaudited)	7
Consolidated Statements of Shareholders' Equity Six months ended July 31, 2020 and 2019 (Unaudited)	8
Consolidated Statements of Cash Flows Six months ended July 31, 2020 and 2019(Unaudited)	9
Notes to Consolidated Financial Statements (Unaudited)	10-17

POLYDEX PHARMACEUTICALS LIMITED
CONSOLIDATED BALANCE SHEETS
JULY 31, 2020
UNAUDITED

(Expressed in United States dollars)

	July 31	January 31
	2020	2020
	(Unaudited)	(Unaudited)
Assets		
Current assets:		
Cash	\$1,041,412	\$370,236
Investments held to maturity (note 3)	228,501	152,643
Trade accounts receivable	835,361	1,332,828
Inventories		
Finished goods	692,938	736,004
Work in progress	17,835	12,120
Raw materials	<u>265,824</u>	<u>277,894</u>
	976,597	1,026,018
Prepaid expenses and other current assets	39,942	78,897
Total current assets	3,121,813	2,960,622
Investments held to maturity (note 3)	764,804	843,728
Property, plant and equipment, net	3,246,734	3,296,971
Deferred taxes (note 8)	62,500	62,500
Due from estate of former shareholder	20,903	20,903
	7,216,754	7,184,724

See accompanying notes.

POLYDEX PHARMACEUTICALS LIMITED
CONSOLIDATED BALANCE SHEETS
JULY 31, 2020
UNAUDITED

(Expressed in United States dollars)

	July 31 2020	January 31 2020
	(Unaudited)	(Unaudited)
Liabilities and Shareholders' Equity		
Current liabilities:		
Accounts payable	\$350,671	\$339,635
Accrued liabilities	255,186	252,155
Income taxes payable	2,904	2,194
Other loans and advances (note 4)	64,275	64,275
Current portion of long-term debt (note 5a)	41,842	66,429
Current portion of lease liabilities (note 5b)	4,432	4,270
Current portion of due to shareholder	52,875	47,760
Total current liabilities	772,185	776,718
Long-term debt (note 5a)	127,994	138,435
Lease liabilities (note 5b)	16,300	18,811
Due to shareholder	240,334	269,708
	384,628	426,954
Total liabilities	1,156,813	1,203,672
Commitments and contingencies (note 6)		
Shareholders' equity:		
Capital stock		
Authorized:		
100,000 Class A preferred shares of \$0.10 each		
899,400 Class B preferred shares of \$0.0167 each		
10,000,000 common shares of \$0.0167 each		
Issued and outstanding:		
899,400 Class B preferred shares (January 31, 2020 - 899,400)	15,010	15,010
3,432,478 common shares (January 31, 2020 - 3,432,478)	57,191	57,192
Contributed surplus	23,816,221	23,816,221
Deficit	(18,167,756)	(18,290,558)
Accumulated other comprehensive income	339,275	383,187
	6,059,941	5,981,052
	\$7,216,754	\$7,184,724

See accompanying notes.

POLYDEX PHARMACEUTICALS LIMITED
CONSOLIDATED STATEMENTS OF OPERATIONS
JULY 31, 2020
UNAUDITED

(Expressed in United States dollars)

	Three Months Ended July 31 2020	Three Months Ended July 31 2019	Six Months Ended July 31 2020	Six Months Ended July 31 2019
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)
Sales	\$1,377,747	\$1,243,883	2,217,069	2,465,367
Cost of goods sold	1,080,888	884,867	1,766,932	1,781,723
Gross profit	296,859	359,016	450,137	683,644
Expenses				
General and administrative	137,270	162,849	273,307	306,582
Interest expense, net	5,973	9,346	12,687	18,031
Selling and promotion	19,717	16,382	27,504	24,464
Depreciation	2,191	2,131	4,319	3,689
Foreign exchange (gain) loss	71,347	51,161	18,208	19,830
Interest and other income	(4,824)	(3,468)	(9,412)	(6,353)
Total expenses	231,674	238,401	326,613	366,243
Income before income taxes	65,185	120,615	123,524	317,401
Provision for income taxes (note 8)				
Current	723	721	723	721
Deferred	-	-	-	-
	723	721	723	721
Net income (loss) for the period	64,462	119,894	122,801	316,680
Unrealized gain (loss) on investments	-	-	-	-
Currency translation adjustment	(43,914)	126,742	(43,914)	(8,719)
Comprehensive income for the period	\$20,548	\$246,636	\$78,887	\$307,961
Per share information:				
Earnings per common share:				
Basic	0.02	0.04	0.04	0.09
Diluted	0.02	0.03	0.04	0.09
Weighted average number of common shares used compute net income per share for the period:				
Basic	3,432,478	3,419,478	3,432,478	3,419,478
Diluted	3,432,478	3,447,282	3,432,478	3,442,867

See accompanying notes.

POLYDEX PHARMACEUTICALS LIMITED
CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY
JULY 31, 2020
UNAUDITED

(Expressed in United States dollars)

	Six Months Ended July 31 2020	Six Months Ended July 31 2019
	(Unaudited)	(Unaudited)
Preferred Shares:		
Balance, beginning and end of period	\$15,010	\$15,010
Common Shares:		
Balance, beginning and end of period	\$57,191	\$56,974
Contributed Surplus:		
Balance, beginning and end of period	\$23,816,221	\$23,807,078
Deficit:		
Balance, beginning of period	(\$18,290,557)	(\$18,541,444)
Net profit for the period	122,801	196,787
Balance, end of period	(\$18,167,756)	(\$18,344,657)
Accumulated Other Comprehensive Income:		
Balance, beginning of period	\$383,189	\$381,258
Unrealized gain on investments available for sale	-	-
Currency translation adjustment for the period	(43,914)	(8,719)
Balance, end of period	\$339,275	\$372,539

See accompanying notes.

POLYDEX PHARMACEUTICALS LIMITED
CONSOLIDATED STATEMENTS OF CASH FLOWS
JULY 31, 2020
UNAUDITED

(Expressed in United States dollars)

	Six Months Ended July 31 2020	Six Months Ended July 31 2019
	(Unaudited)	(Unaudited)
Cash provided by (used in):		
Operating activities:		
Net profit for the period	\$122,801	\$316,680
Add (deduct) items not affecting cash:		
Depreciation and amortization	138,012	139,425
Deferred income taxes (note 8)	---	-
Net change in non-cash working capital balances related to operations	561,777	78,881
Cash provided by operating activities	822,590	534,986
Investing activities:		
Additions to property, plant and equipment	(130,033)	(221,073)
Decrease in due from shareholder	-	-
Increase in investments available for sale	(7,802)	(6,353)
Proceeds (Acquisition) of investments available for sale	-	(603,083)
Cash used in investing activities	(137,835)	(830,509)
Financing activities:		
Repayment of long-term debt	(31,633)	(31,277)
Proceeds (Repayment) of capital lease obligations, net	(2,005)	(2,862)
Decrease in due to shareholder	(24,259)	(10,702)
Cash used in financing activities	(57,897)	(44,841)
Effect of exchange rate changes	44,318	10,825
Net increase in cash and cash equivalents	671,176	(329,539)
Cash, beginning of year	370,236	1,593,728
Cash, end of period	\$1,041,412	\$1,264,189

See accompanying notes.

POLYDEX PHARMACEUTICALS LIMITED
QUARTERLY REPORT
JULY 31, 2020
UNAUDITED

ITEM III NOTES TO INTERIM FINANCIAL STATEMENTS

1. Basis of Presentation:

The information contained in the interim consolidated financial statements is condensed from that which would appear in annual consolidated financial statements. The interim consolidated financial statements included herein should be read in conjunction with the unaudited financial statements, and notes thereto, and other financial information contained in the Annual Report for the fiscal year ended January 31, 2020 as found on the Polydex Pharmaceuticals Limited (the “Company”) website, www.polydex.com. The unaudited interim consolidated financial statements as of July 31, 2020 and 2019 include all normal recurring adjustments which management considers necessary for a fair presentation. The results of operations for the interim periods presented are not necessarily indicative of the results that may be expected for the entire fiscal year. The interim consolidated financial statements include the accounts and transactions of the Company and its majority owned subsidiaries in which the Company has equal to or more than a 50% ownership interest and exercises control.

Management has reviewed subsequent events, and there were no material subsequent events since July 31, 2020 that would require recognition or note disclosures in these financial statements.

2. Significant Accounting Policies:

Basis of consolidation

The interim consolidated financial statements include the accounts of the Company and its subsidiaries, all of which are 100% owned. All inter-company accounts and transactions have been eliminated on consolidation.

Cash and cash equivalents

Cash and cash equivalents include cash and short-term deposits with maturities of less than three months at the date of purchase.

Trade receivables

The Company has trade receivables from selling manufactured goods at agreed upon prices. Normal receivables are due between 30 and 120 days after the issuance of the invoice. The receivables from export sales are insured by Export Development Canada. At quarter end, substantially all of the receivables were insured and no allowance was required.

Use of estimates

The preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at

POLYDEX PHARMACEUTICALS LIMITED
QUARTERLY REPORT
JULY 31, 2020
UNAUDITED

the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. Significant accounting estimates relate to the allowance for doubtful accounts, depreciation and amortization rates, and asset impairment charges.

Inventories

Inventories of raw materials are stated at the lower of cost and net realizable value, cost being determined on a first-in, first-out basis. Work-in-process and finished goods are valued at the lower of cost and net realizable value, and include the cost of raw materials, direct labor and fixed and variable overhead expenses fixed overhead expenses based on normal manufacturing capacity.

Investments held-to-maturity

Investments are classified as held-to-maturity and carried at amortized cost when management has the positive intent and ability to hold them to maturity. Investments held-to-maturity consisted of guaranteed interest rate contracts with varying interest rates and are stated at amortized cost, based on interest earned. Interest income is included in other income in the consolidated statements of operations and comprehensive income as it is earned.

Property, plant and equipment and patents and intangible assets

Property, plant and equipment are recorded at cost less accumulated depreciation. Depreciation is provided on a straight-line basis over the estimated useful lives of the assets as follows:

- Buildings 15 to 25 years
- Machinery and equipment 3 to 10 years

Useful life is the period over which the asset is expected to contribute to the Company's future cash flows. The Company reviews the recoverability of its long-lived assets when events or changes in circumstances occur that indicate that the carrying value of the asset may not be recoverable. The assessment of possible impairment is based on the Company's ability to recover the carrying value of the asset from the expected future pre-tax cash flows of the related operations. If these cash flows are less than the carrying value of such asset, an impairment loss is recognized for the difference between estimated fair value and carrying value. Impairment losses are not reversible.

Costs related to plant refurbishments and equipment upgrades that represent improvements to existing facilities are capitalized. Costs related to repair and maintenance of buildings and equipment are expensed. The Company has no major planned maintenance activity.

Revenue recognition

All revenue is from sales of bulk manufactured products and is measured based on a consideration specified in a contract with a customer and excludes any amounts collected on behalf of third parties, such as taxes assessed by a governmental authority. Revenue is recognized when title and risk of

POLYDEX PHARMACEUTICALS LIMITED
QUARTERLY REPORT
JULY 31, 2020
UNAUDITED

ownership of products pass to the customer. Title and risk of ownership pass to the customer pursuant to the applicable sales contract, either upon shipment of product or upon receipt by the customer.

Product sold in bulk quantities is tested, prior to release for shipment, to ensure that it meets customer specifications, and in many cases, customers receive samples for their own testing. Approval is obtained from the customer prior to shipping.

Comprehensive income

The Company discloses comprehensive income in their financial statements using the single statement method. In addition to items included in net income, comprehensive income includes items currently charged or credited directly to shareholders' equity, such as foreign currency translation adjustments.

Shipping and handling costs

Shipping and handling costs incurred by the Company for shipment of products to customers are included in cost of goods sold.

Research and development

Research and development costs are expensed as incurred and are stated net of investment tax credits earned.

Foreign currency translation

The functional currency of the Company's Canadian operations has been determined to be the Canadian dollar. All asset and liability accounts of the Company except capital stock have been translated into United States dollars using the current exchange rates at the interim consolidated balance sheet dates. Capital stock is recorded at historical rates. Revenue and expense items are translated using the average exchange rates for the period. The resulting gains and losses have been reported separately as accumulated other comprehensive income within shareholders' equity.

Derivative financial instruments

The Company's Canadian operations from time to time enters into foreign exchange contracts, to manage exposure to currency rate fluctuations related to expected future cash flows. The Company does not engage in speculative trading of derivative financial instruments. The foreign exchange contracts are not designated as hedging instruments, and as a result all foreign exchange contracts are marked to market and the resulting gains and losses are recorded in the consolidated statements of operations in each reporting period. Unrealized gains and losses are included in accrued liabilities in the consolidated balance sheets and in net change in non-cash working capital balances related to operations in the consolidated statements of cash flows. For the fiscal period ended July 31, 2020 the Company has not entered into any derivative financial instruments.

POLYDEX PHARMACEUTICALS LIMITED
QUARTERLY REPORT
JULY 31, 2020
UNAUDITED

Stock options

The Company uses the fair value accounting methodology to apply recognition provisions to employee stock options granted, modified or settled. Compensation expense is recorded at the date stock options are granted. The amount of compensation expense is determined by estimating the fair value of the options granted using the Black-Scholes option pricing model.

Income taxes

The Company accounts for income taxes by recognizing deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the consolidated financial statements or tax returns. Deferred income taxes are provided using the liability method. Under the liability method, deferred income taxes are recognized for all significant temporary differences between the tax and financial statement bases of assets and liabilities.

Effects of changes in enacted tax laws on deferred tax assets and liabilities are reflected as adjustments to tax expense in the period of enactment. Deferred tax assets may be reduced if deemed necessary based on a judgmental assessment of available evidence, by a valuation allowance for the amount of any tax benefits which are more likely, based on current circumstances, not expected to be realized.

Income per common share

Basic earnings per common share is computed using the weighted average number of common shares outstanding of 3,432,478 for the three months and six months ended July 31, 2020 (2019 - 3,419,478). Diluted earnings per common share is computed using the weighted average number of common shares outstanding adjusted for the incremental shares, using the treasury stock method, attributed to outstanding options to purchase common stock. No incremental shares were used in the calculation of year to date diluted earnings per share as at July 31, 2020 and 23,389 incremental shares were included for the six months ended July 31, 2019. No incremental shares were used in the calculation of diluted earnings per share for the three months ended July 31, 2020, and 27,803 incremental shares were included for the three months ended July 31, 2019.

3. Investments Held-to-Maturity:

Investments available for sale, at fair value, consist of the following:

	July 31 2020	January 31 2020
	\$	\$
Guaranteed interest contracts with interest rates varying from 1.9% to 2.55% per annum and varying maturities from December 2020 to February 2027	993,305	996,371
	993,305	996,371

POLYDEX PHARMACEUTICALS LIMITED
QUARTERLY REPORT
JULY 31, 2020
UNAUDITED

Contractual maturities of investments held-to-maturity at July 31, 2020 are as follows:

	Net Carrying Amount
Due in one year or less	228,501
Due beyond one year	764,804
	993,305

4. Other loans and advances:

Other loans and advances consist of the following:

	July 31 2020 \$	January 31 2020 \$
Customer advance	64,275	64,275

The advance from a customer is non-interest bearing, unsecured, and is repayable on demand.

5. Long term debt obligations:

[a] Bank term loans consist of the following:

	July 31 2020 \$	January 31 2020 \$
Bank term loan #1 payable in monthly installments of Cdn \$5,594 (U.S. \$4,173) principal and interest at the Canadian bank's fixed rate of 4.98%	24,664	49,371
Bank term loan #2 payable in monthly installments of Cdn \$2,527 (U.S. \$1,885) principal and interest at the Canadian bank's fixed rate of 3.97%	145,172	155,493
	169,836	204,864
Less: current portion	41,842	66,429
	127,994	138,435

POLYDEX PHARMACEUTICALS LIMITED
QUARTERLY REPORT
JULY 31, 2020
UNAUDITED

Bank term loan #1 was arranged in January 2016 for 60 months at a fixed rate of prime plus 1.50% (2019 – 4.20%). On January 29, 2019 the loan was renewed at a fixed rate of 4.98% per annum maturing January 29, 2021.

Bank term loan #2 was arranged in December 2017 for 120 months at a fixed rate of prime plus 1.50% (2019 and 2018 - 3.97%).

The Company also obtained an operating loan facility of Cdn \$300,000 (USD – \$223,814) for working capital purposes, of which none was utilized at January 31, 2020 and July 31, 2020. This Canadian operating facility bears interest at the Canadian bank's prime lending rate plus 2.15%.

Bank indebtedness and facility are collateralized by a general security agreement over the Company's assets and a collateral mortgage of Cdn \$500,000 (USD – \$373,023) on the Company's building located in Toronto, Canada.

The company was in compliance with all covenants as of July 31, 2020.

Interest expense for the six months on the loans was \$2,900 (2019 - \$5,458).

Principal repayments on the bank loan are as follows:

	\$
2021	41,842
2022	17,872
2023	18,594
2024	19,261
2025	19,980
Thereafter	52,287
	<hr/> 169,836 <hr/>

POLYDEX PHARMACEUTICALS LIMITED
QUARTERLY REPORT
JULY 31, 2020
UNAUDITED

[b] Finance lease obligations consist of the following:

	July 31 2020	January 31 2020
	\$	\$
Lease liability, repayable in quarterly instalments of \$2,134 (U.S. \$1,592) bearing interest at 10.15 % and maturing in 2024	20,732	23,081
Less current portion	4,432	4,270
	16,300	18,811

Future minimum annual lease payments on the finance lease obligations including interest are as follows:

	\$
2021	6,371
2022	6,371
2023	6,371
2024	6,371
Total minimum lease payments	25,484
Less amount representing imputed interest	4,752
	20,732

Interest expense for the 6 months ended July 31, 2020 for finance lease obligations was \$635 (2019 - \$658).

6. Commitments and Contingencies:

In July of 2013, a subsidiary of the Company, Chemdex Inc., renewed its supply agreement with an existing customer and signed an agreement to supply raw materials for an additional product. The agreement is for a period of ten years, renewable for another ten years, and provides the customer with exclusive rights to these raw materials in the United States.

The Company has committed to purchase approximately \$320,000 of partially finished product from a contract manufacturer.

There were no other material commitments or contingencies outstanding as of July 31, 2020.

POLYDEX PHARMACEUTICALS LIMITED
QUARTERLY REPORT
JULY 31, 2020
UNAUDITED

7. Stock-based Employee Compensation:

The Company uses the fair value method to account for awards of stock-based employee compensation. No stock-based employee compensation expense was recorded during the period from February 1, 2020 to July 31, 2020, because there were no options granted during this period. Similarly, no stock-based employee compensation expense was recorded during the period from February 1, 2019 to July 31, 2019, because there were no options granted during that period.

8. Provision for Income Taxes

The Company's income tax provision for July 31, 2020 relates to income taxes owing at its United State's subsidiary Chemdex, Inc.

9. Segmented Information:

Total revenue by significant customer:

	Six Months Ended July 31 2020	Six Months Ended July 31 2019
	\$	\$
Customer A	521,859	--
Customer B	216,398	430,859
Customer C	196,075	190,428
Customer D	140,881	334,338
Customer E	130,510	108,971
Customer F	77,840	81,223
Customer G	7,000	516,804
	1,290,563	1,662,633

Sales by geographic destination:

	Six Months Ended July 31 2020	Six Months Ended July 31 2019
	\$	\$
United States	1,253,654	1,184,913
Europe	662,028	570,955
Canada	160,047	335,179
Other	141,340	252,545
Pacific Rim	--	121,775
	2,217,069	2,465,367

POLYDEX PHARMACEUTICALS LIMITED
QUARTERLY REPORT
JULY 31, 2020
UNAUDITED

ITEM IV MANAGEMENT DISCUSSION AND ANALYSIS

The Company's fiscal year ends on January 31st of each year. In this report, fiscal year 2021 refers to the Company's fiscal year ending January 31, 2021. The following discussion should be read in conjunction with the July 31, 2020 interim consolidated financial statements and notes thereto included elsewhere in this report. Operating results for the three and six months ended July 31, 2020 are not necessarily indicative of the results that may be expected for the fiscal year ending January 31, 2021. For further information, refer to the Polydex Pharmaceuticals Limited Annual Report on our website, www.polydex.com. The Company's financial statements are prepared in substantial accordance with United States generally accepted accounting principles. All amounts are in United States dollars, unless otherwise denoted.

Overview

The Company is engaged in the manufacture of bulk pharmaceutical intermediates for the worldwide veterinary pharmaceutical industry and also the manufacture and marketing of biotechnology-based products for the human pharmaceutical market. The Company conducts its business operations through its wholly-owned subsidiary Chemdex, Inc. and its corporate division operating as Dextran Products. (On May 1, 2017 Dextran Products Limited and Polydex Chemicals (Canada) Limited were amalgamated into the parent company Polydex Pharmaceuticals Limited).

The manufacture and sale of bulk quantities of dextran and derivative products for sale to large pharmaceutical companies throughout the world is conducted through the Company's operating division, Dextran Products in Canada. Chemdex, Inc. in the United States provides ferric hydroxide and hydrogenated dextran to a customer pursuant to a definitive supply agreement.

Management Objectives for Fiscal 2021:

Management considers the current quarter's results acceptable in light of the continued impact that the COVID pandemic is having on the worldwide economy.

Increased demand for Native Dextran for new applications continued in the second quarter of fiscal 2021. The development work has been ongoing for several years and management is pleased to see progress. More orders have been received for Q3 and are expected for Q4.

POLYDEX PHARMACEUTICALS LIMITED
 QUARTERLY REPORT
 JULY 31, 2020
 UNAUDITED

Results of Operations

Three and six months ended July 31, 2020 compared to three and six months ended July 31, 2019:

	Three Months Ended July 31, 2020	Three Months Ended July 31, 2019	Variance	Six Months Ended July 31, 2020	Six Months Ended July 31, 2019	Variance
Net Income	\$64,462	\$119,894	(46)%	\$122,801	\$316,680	(61)%
Income per Share:						
Basic	\$0.02	\$0.04		\$0.04	\$0.09	
Diluted	\$0.02	\$0.03		\$0.04	\$0.09	

The decrease in net income for the second quarter continues to be primarily a result of decreased gross margins. The product mix has changed from the prior year with powdered sales in the current fiscal year not as strong as the prior year.

	Three Months Ended July 31, 2020	Three Months Ended July 31, 2019	Variance	Six Months Ended July 31, 2020	Six Months Ended July 31, 2019	Variance
Sales	\$1,377,747	\$1,243,883	11%	\$2,217,069	\$2,465,367	(10)%

Sales in the second quarter of fiscal 2021 increased slightly compared to the second quarter of fiscal 2020. This is mainly due to the two week shut down in April 2020 from the pandemic that delayed shipments to the second quarter. The decrease in sales for the year to date of fiscal 2021 compared to fiscal 2020 is primarily due to change in product mix.

POLYDEX PHARMACEUTICALS LIMITED
 QUARTERLY REPORT
 JULY 31, 2020
 UNAUDITED

	Three Months Ended July 31, 2020	Three Months Ended July 31, 2019	Variance	Six Months Ended July 31, 2020	Six Months Ended July 31, 2019	Variance
Gross Profit	\$296,859	\$359,016	(17)%	\$450,137	\$683,644	(34)%
Percentage of sales	22%	29%		20%	28%	

The decrease in gross profit percentage and dollar amounts in the second quarter and year to date of fiscal year 2021 were primarily due to a drop in powdered sales from a year ago. Raw materials continued to be a concern in Q2 with some instability of delivery but due to management's regular communication with suppliers this seems to be less of an issue on a go forward basis. COVID 19 continues to impact the cost of certain raw materials that ultimately affect our gross profit. It is important to remember, however, the COVID 19 situation is extremely fluid and so management continues to monitor the situation closely.

	Three Months Ended July 31, 2020	Three Months Ended July 31, 2019	Variance	Six Months Ended July 31, 2020	Six Months Ended July 31, 2019	Variance
Selling, promotion, general and administrative expenses	\$156,987	\$179,231	(12)%	\$300,811	\$330,046	(9)%

The decrease in the second quarter of fiscal year 2021 and year to date results is primarily due to the change in foreign exchange rates compared to the year end rate.

	Three Months Ended July 31, 2020	Three Months Ended July 31, 2019	Variance	Six Months Ended July 31, 2020	Six Months Ended July 31, 2019	Variance
Research and Development expenditures	---	---	---	---	---	---

POLYDEX PHARMACEUTICALS LIMITED
 QUARTERLY REPORT
 JULY 31, 2020
 UNAUDITED

During fiscal year 2010 all of the Company's research into Ushercell was halted, with only some patent expenses being incurred and paid. Since that time further patent fees have been curtailed, with only smaller patent maintenance fees being expensed as incurred.

	Three Months Ended July 31, 2020	Three Months Ended July 31, 2019	Variance	Six Months Ended July 31, 2020	Six Months Ended July 31, 2019	Variance
Depreciation and amortization expense	\$70,293	\$71,484	(1.7)%	\$138,012	\$139,424	(1.0)%

Depreciation and amortization remains virtually unchanged comparing both the current quarter and year to date figures to the prior fiscal periods.

	Three Months Ended July 31, 2020	Three Months Ended July 31, 2019	Variance	Six Months Ended July 31, 2020	Six Months Ended July 31, 2019	Variance
Interest expense	\$5,973	\$9,346	(36)%	\$12,687	\$18,031	(30)%

The decrease in interest expense in the second quarter of fiscal year 2021 continues to be due to the decreased value in the Canadian dollar as the company continues to pay down loans. The drop in US prime rate also affects the drop in interest paid on the shareholder loan.

	Three Months Ended July 31, 2020	Three Months Ended July 31, 2019	Variance	Six Months Ended July 31, 2020	Six Months Ended July 31, 2019	Variance
Foreign exchange (gain) loss	\$71,347	\$51,161	39%	\$18,208	\$19,830	(8)%

The foreign exchange loss for the second quarter of fiscal year 2021 was due to the strengthened Canadian dollar from the first quarter of the year. The volatility of these exchange rates increase or decrease the value of exchange affected amounts in the Company's Canadian division, Dextran Products, especially U.S. denominated sales.

POLYDEX PHARMACEUTICALS LIMITED
 QUARTERLY REPORT
 JULY 31, 2020
 UNAUDITED

	Three Months Ended July 31, 2020	Three Months Ended July 31, 2019	Variance	Six Months Ended July 31, 2020	Six Months Ended July 31, 2019	Variance
Interest and investment income	\$4,824	\$ 3,468	39%	\$9,412	\$6,353	48%

Interest and other income increased in the current quarter and year to date. The company invests in a series of guaranteed interest rate contracts. The company transferred the equivalent of \$500,000 Canadian dollars to its investments in December 2019. These contracts provide consistent and steady returns with no risk of capital erosion.

	Three Months Ended July 31, 2020	Three Months Ended July 31, 2019	Variance	Six Months Ended July 31, 2020	Six Months Ended July 31, 2019	Variance
Income tax expense						
Current	\$723	\$721		\$723	\$721	
Deferred	---	---		---	---	
Income taxes	\$723	\$721	--%	\$723	\$721	--%

The current tax provision for the three months and year to date ended July 31, 2020 relates to income taxes in the Company's United States subsidiary, Chemdex, Inc.

POLYDEX PHARMACEUTICALS LIMITED
QUARTERLY REPORT
JULY 31, 2020
UNAUDITED

Liquidity and Capital Resources

As of July 31, 2020, the Company had cash and investments of \$2,034,717 compared to cash and investments of \$1,366,608 at January 31, 2020. In the first six months of fiscal year 2021 the Company generated cash of \$822,590 in its operating activities, compared to \$534,986 for the six months of fiscal year 2020. The increase in the generation of cash for operations during the current year is primarily due to timing of receivables collections.

The Company's working capital increased to \$2,339,363 from \$2,183,905 as at January 31, 2020. The working capital ratio increased to 4.03 to 1 as of July 31, 2020 compared to 3.81 to 1 as of January 31, 2020.

As of July 31, 2020, the Company had accounts receivable of \$835,361 and inventory of \$976,597 compared to \$1,332,828 and \$1,026,018 respectively at January 31, 2020 and \$903,514 and \$1,309,812 respectively at July 31, 2019. Accounts receivable decreased due to the timing of receipts, while inventory decreased slightly due to orders shipped at the end of the quarter.

At July 31, 2020, the Company had accounts payable of \$350,671 compared to \$339,634 at January 31, 2020 and \$579,784 at July 31, 2019. Accounts payable increased due to timing of payments.

During the second quarter of fiscal year 2021, capital expenditures totaled \$72,266 as compared to \$142,834 in the second of fiscal year 2020. Expenditures in the second quarter of fiscal 2021 related to plant equipment. Additional expenditures on capital equipment are possible for the remainder of fiscal 2021.

The change in accumulated other comprehensive income of the Company is primarily attributable to the currency translation adjustment of Dextran Products. Dextran Products' functional currency is the Canadian dollar. This currency translation adjustment arises from the translation of Dextran Products' financial statements to U.S. dollars.

The increase in capital lease obligations from January 31, 2020 is due to new capital leases for office equipment in the first quarter of 2019. Despite this addition overall long term debt decreased as a result of continued loan repayments.

Changes in the relative values of the Canadian dollar and the United States dollar occur from time to time and may, in certain instances, materially affect the Company's results of operations.

The Company does not believe that the impact of inflation and changing prices has had a material effect on its operations or financial results at any time in the last three years.

POLYDEX PHARMACEUTICALS LIMITED
QUARTERLY REPORT
JULY 31, 2020
UNAUDITED

Related Party Transactions

The amount due from shareholder as of July 31, 2020 was \$312,635 as compared to \$304,292 at January 31, 2020, including accrued interest. The Company has taken a cumulative provision of \$541,732 at July 31, 2020 (January 31, 2020 \$533,930) against accrued interest on the Loan and the other amounts receivable from the estate as noted below. Obligations with respect to the Loan transferred to the estate of Thomas C. Usher upon his death in February 2005.

Thomas C. Usher also owed \$250,000 to a subsidiary of the Company, Novadex International Limited, as of July 31, 2020, pursuant to a non-interest bearing loan with no specific repayment terms. The outstanding amount of this loan has not changed from January 31, 2020. The amounts continue to remain owing from the estate of Thomas C. Usher.

As of July 31, 2020, Thomas C. Usher, now through his estate, had pledged 243,263 common shares of the Company as security for these amounts owing to the Company. These common shares had a market value of \$209,206 at July 31, 2020, based on the closing price of the Company's common shares on the Pink Sheets quotation service on July 31, 2020. The Company intends to continue to hold the pledged assets as collateral until the amounts owing discussed above are repaid.

The Company had a commitment to pay an amount equal to one year's salary, \$110,000, to Thomas C. Usher's estate. The amount owing on this commitment as at July 31, 2020 is \$1,012 (January 31, 2020 – \$3,532).

The Company also has an outstanding loan payable to the Estate of Ruth Usher, a former director and the widow of Thomas C. Usher. The amount due from the Company pursuant to this loan decreased to \$293,188 as at July 31, 2020 from \$317,468 at January 31, 2020 due to monthly payments by the Company, less interest charges.

Off-Balance Sheet Arrangements

The Company has no off-balance sheet arrangements.

Critical Accounting Policies

The Company's interim consolidated financial statements are prepared in substantial accordance with accounting principles generally accepted in the United States, applied on a consistent basis. The critical accounting policies include the use of estimates of allowance for doubtful accounts, the useful lives of assets and the realizability of deferred tax assets.

POLYDEX PHARMACEUTICALS LIMITED
QUARTERLY REPORT
JULY 31, 2020
UNAUDITED

Management is required to make estimates and assumptions in preparing the consolidated financial statements that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the periods. The actual results could differ from these estimates. Significant estimates made by management include the calculation of reserves for uncollectible accounts, inventory allowances, useful lives of long-lived assets and the realizability of deferred tax assets.

Revenue Recognition

Revenue results from sales of bulk manufactured products and is recognized when title and risk of ownership of products pass to the customer. Title and risk of ownership pass to the customer pursuant to the applicable sales contract, either upon shipment of product or upon receipt by the customer. Since returns are rare and generally not accepted, management has not made provision for returns. In addition, product sold in bulk quantities is tested, prior to release for shipment, to ensure that it meets customer specifications, and in many cases, customers receive samples for their own testing. Approval is obtained from the customer prior to shipping.

Allowance for Doubtful Accounts

Accounts receivable is stated net of allowances for doubtful accounts. Allowances for doubtful accounts are determined by each reporting unit on a specific item basis. Management reviews the credit worthiness of individual customers and past payment history to determine the allowance for doubtful accounts. Since the majority of sales at Dextran Products are export, Dextran Products maintains credit insurance through a crown corporation which is supported by the Canadian government, for the majority of its customers' receivables. There has been no allowance for doubtful accounts during the past two fiscal years.

Long-Lived Assets

Long-lived assets are stated at cost, less accumulated depreciation or amortization computed using the straight-line method based on their estimated useful lives ranging from three to twenty five years. Useful life is the period over which the asset is expected to contribute to the Company's future cash flows. A significant change in estimated useful lives could have a material impact on the results of operations. The Company reviews the recoverability of its long-lived assets, including buildings, equipment and other intangible assets, when events or changes in circumstances occur that indicate that the carrying value of the asset may not be recoverable. The assessment of possible impairment is based on the Company's ability to recover the carrying value of the asset from the expected future pre-tax cash flows of the related operations. If these cash flows are less than the carrying value of such asset, an impairment loss is recognized for the difference between estimated fair value and carrying

POLYDEX PHARMACEUTICALS LIMITED
QUARTERLY REPORT
JULY 31, 2020
UNAUDITED

value. The measurement of impairment requires management to make estimates of these cash flows related to long-lived assets as well as other fair value determinations.

Deferred Tax Assets

The Company has recorded a valuation allowance on deferred tax assets where there is uncertainty as to the ultimate realization of the future tax deduction. The Company has incurred capital losses, which are only deductible against capital gains. It is not certain that Dextran Products will realize capital gains in the future to use these Canadian capital loss deductions.

Changes in Accounting Policies

No changes in accounting principles or their application have been implemented in the reporting period that would have a material effect on reported income.

POLYDEX PHARMACEUTICALS LIMITED
QUARTERLY REPORT
JULY 31, 2020
UNAUDITED

ITEM V LEGAL PROCEEDINGS

Not applicable.

.

ITEM VI DEFAULTS UPON SENIOR SECURITIES

Not applicable.

ITEM VII OTHER INFORMATION

Not applicable.

ITEM VIII EXHIBITS

Not applicable

POLYDEX PHARMACEUTICALS LIMITED
QUARTERLY REPORT
JULY 31, 2020
UNAUDITED

ITEM IX CERTIFICATIONS

I, George G. Usher, certify that:

1. I have reviewed this quarterly disclosure statement of Polydex Pharmaceuticals Limited;
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

September 15, 2020

/s/ George G. Usher

Chairman, President and Chief Executive Officer
Polydex Pharmaceuticals Limited

POLYDEX PHARMACEUTICALS LIMITED
QUARTERLY REPORT
JULY 31, 2020
UNAUDITED

ITEM IX CERTIFICATIONS (Continued)

I, David P.M. Jamestee, certify that:

1. I have reviewed this quarterly disclosure statement of Polydex Pharmaceuticals Limited;
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

September 15, 2020

/s/ David P.M. Jamestee
Chief Financial Officer
Polydex Pharmaceuticals Limited